SOLIGENIX, INC. — Director's Dealing 2019

Jul 10, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SOLIGENIX, INC. (SNGX)
CIK: 0000812796
Period of Report: 2019-06-28

Reporting Person: Pearson Mark E. (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-06-28	Common Stock	A	78338	$0.71	Acquired	78338	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2500000	Direct

Footnotes

F1: These securities were issued in lieu of cash compensation payable for services rendered, with the number of shares issued being calculated based upon the closing price of $0.71 on June 28, 2019. The transaction is exempt under Rule 16b-3 of the Securities Exchange Act of 1934.

F2: These securities are held by Altamont Pharmaceutical Holdings, LLC, a company for which the reporting person serves as general partner and chief executive officer. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or any other purpose.